146 related articles for article (PubMed ID: 29393986)
21. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
Rogers KA; Huang Y; Ruppert AS; Salem G; Stephens DM; Heerema NA; Andritsos LA; Awan FT; Byrd JC; Flynn JM; Maddocks KJ; Jones JA
Br J Haematol; 2018 Jan; 180(2):259-266. PubMed ID: 29193006
[TBL] [Abstract][Full Text] [Related]
22. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
Li Z; Li F; Yi S; Gu Z; Yu Z; Xu Y; Feng X; Liu W; Zou D; Qi J; Zhan F; Qiu L
BMC Cancer; 2015 Jul; 15():555. PubMed ID: 26219471
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: Results of the BEN-001 study].
Stadnik EA; Strugov VV; Andreeva TO; Virts YV; Rumyantsev AM; Mirolyubova YV; Butylin PA; Zaritsky AY
Ter Arkh; 2017; 89(7):57-64. PubMed ID: 28766542
[TBL] [Abstract][Full Text] [Related]
24. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
[TBL] [Abstract][Full Text] [Related]
25. Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia.
Šimkovič M; Vodárek P; Motyčková M; Écsiová D; Rozsívalová P; Móciková H; Štěpánková P; Sýkorová A; Hrochová K; Vrbacký F; Belada D; Žák P; Smolej L
Eur J Clin Invest; 2021 Apr; 51(4):e13421. PubMed ID: 33022756
[TBL] [Abstract][Full Text] [Related]
26. A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities.
Danilov AV; Lewis LD; Lansigan F; Roudaia L; Findley DL; Jones SY; Highhouse B; Beaulieu BB; Brown JR
Br J Haematol; 2017 Sep; 178(5):820-823. PubMed ID: 27377970
[No Abstract] [Full Text] [Related]
27. Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.
Nabhan C; Mato A; Flowers CR; Grinblatt DL; Lamanna N; Weiss MA; Davids MS; Swern AS; Bhushan S; Sullivan K; Flick ED; Kiselev P; Sharman JP
BMC Cancer; 2017 Mar; 17(1):198. PubMed ID: 28302090
[TBL] [Abstract][Full Text] [Related]
28. Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia.
Casado LF; Hernández JÁ; Jarque I; Echave M; Casado MA; Castro A
Eur J Haematol; 2018 Mar; 100(3):264-272. PubMed ID: 29226472
[TBL] [Abstract][Full Text] [Related]
29. Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.
Chaoui D; Choquet S; Sanhes L; Mahé B; Hacini M; Fitoussi O; Arkam Y; Orfeuvre H; Dilhuydy MS; Barry M; Jourdan E; Dreyfus B; Tempescul A; Leprêtre S; Bardet A; Leconte P; Maynadié M; Delmer A
Leuk Lymphoma; 2017 Jun; 58(6):1366-1375. PubMed ID: 28271952
[TBL] [Abstract][Full Text] [Related]
30. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.
Dartigeas C; Van Den Neste E; Léger J; Maisonneuve H; Berthou C; Dilhuydy MS; De Guibert S; Leprêtre S; Béné MC; Nguyen-Khac F; Letestu R; Cymbalista F; Rodon P; Aurran-Schleinitz T; Vilque JP; Tournilhac O; Mahé B; Laribi K; Michallet AS; Delmer A; Feugier P; Lévy V; Delépine R; Colombat P; Leblond V; ;
Lancet Haematol; 2018 Feb; 5(2):e82-e94. PubMed ID: 29275118
[TBL] [Abstract][Full Text] [Related]
31. Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.
Iannitto E; Morabito F; Mancuso S; Gentile M; Montanini A; Augello A; Bongarzoni V; D'Arco A; Di Renzo N; Fazzi R; Franco G; Marasca R; Mulè A; Musso M; Musto P; Pennese E; Piccin A; Rota-Scalabrini D; Visani G; Rigacci L
Br J Haematol; 2011 May; 153(3):351-7. PubMed ID: 21371003
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of the Combination of Rituximab and Standard Chemotherapeutic Regimens in Previously Untreated Patients with Chronic Lymphocytic Leukaemia in Real-Life: Results from a Noninterventional Study (CILI Study).
Szász R; Altai E; Pál K; Dombi P; Iványi J; Jakucs J; Jóni N; Illés Á; Tárkányi I; Szerafin L; Nagy Z; Farkas P; Nagy Á; Piukovics K; Ujj G; Schneider T
Pathol Oncol Res; 2019 Apr; 25(2):535-540. PubMed ID: 30361908
[TBL] [Abstract][Full Text] [Related]
33. Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.
Ninkovic M; Fiegl M; Mian M; Mondello P; Kocher F; Waldthaler C; Verdorfer I; Steurer M; Gastl G; Pircher A
Anticancer Res; 2015 Sep; 35(9):5129-39. PubMed ID: 26254418
[TBL] [Abstract][Full Text] [Related]
34. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial.
Robak T; Błoński J; Skotnicki AB; Piotrowska M; Wróbel T; Rybka J; Kłoczko J; Bołkun Ł; Budziszewska BK; Walczak U; Uss A; Fidecka M; Smolewski P
Eur J Haematol; 2018 May; 100(5):465-474. PubMed ID: 29427355
[TBL] [Abstract][Full Text] [Related]
35. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ
Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194
[TBL] [Abstract][Full Text] [Related]
36. Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.
Al-Sawaf O; Bahlo J; Robrecht S; Fischer K; Herling CD; Hoechstetter M; Fink AM; von Tresckow J; Langerbeins P; Cramer P; Stilgenbauer S; Wendtner CM; Eichhorst B; Hallek M; Goede V
Br J Haematol; 2018 Dec; 183(5):727-735. PubMed ID: 30460980
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.
Assouline S; Buccheri V; Delmer A; Gaidano G; Trneny M; Berthillon N; Brewster M; Catalani O; Li S; McIntyre C; Sayyed P; Badoux X
Lancet Haematol; 2016 Mar; 3(3):e128-38. PubMed ID: 26947201
[TBL] [Abstract][Full Text] [Related]
38. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
Main C; Pitt M; Moxham T; Stein K
Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
[TBL] [Abstract][Full Text] [Related]
39. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.
Visco C; Finotto S; Pomponi F; Sartori R; Laveder F; Trentin L; Paolini R; Di Bona E; Ruggeri M; Rodeghiero F
Am J Hematol; 2013 Apr; 88(4):289-93. PubMed ID: 23450436
[TBL] [Abstract][Full Text] [Related]
40. Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Morabito F; Tripepi G; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Bossio S; Varettoni M; Murru R; Chiarenza A; Visentin A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Al-Janazreh H; Vigna E; Martino EA; Mendicino F; Cassin R; D'Arrigo G; Galimberti S; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Neri A; Fronza G; Monti P; Menichini P; Cutrona G; Jaksic O; Rossi D; Di Raimondo F; Cuneo A; Gaidano G; Polliack A; Trentin L; Foà R; Ferrarini M; Gattei V; Gentile M
Eur J Haematol; 2021 Apr; 106(4):493-499. PubMed ID: 33378569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
